argenex Q4 Earnings Call Highlights

In Q&A, Massey referenced prior company estimates that seronegative MG could expand the addressable population by about 11,000 patients and ocular MG by about 7,000 patients, noting the ocular figure represented those believed eligible for VYVGART based on market research rather than the entire ocular MG population.Chief Operating Officer Karen Massey said the company views the ADAPT OCULUS results as a “meaningful opportunity” to broaden VYVGART’s reach in MG alongside progress in seronegative MG. She reit ...